Share on StockTwits

AstraZeneca plc (LON:AZN) was upgraded by analysts at Credit Suisse to a “neutral” rating in a research report issued to clients and investors on Tuesday, American Banking and Market News reports. The firm currently has a GBX 4,800 ($80.65) target price on the stock, up from their previous target price of GBX 4,000 ($67.20). Credit Suisse’s price objective would suggest a potential upside of 3.62% from the company’s current price.

AstraZeneca plc (LON:AZN) traded down 0.73% during mid-day trading on Tuesday, hitting GBX 4632.50. 7,411,943 shares of the company’s stock traded hands. AstraZeneca plc has a one year low of GBX 3028.50 and a one year high of GBX 4296.50. The stock has a 50-day moving average of GBX 3946. and a 200-day moving average of GBX 3699.33. The company’s market cap is £58.416 billion.

A number of other analysts have also recently weighed in on AZN. Analysts at Societe Generale upgraded shares of AstraZeneca plc to a “hold” rating in a research note on Monday. They now have a GBX 4,661 ($78.31) price target on the stock. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc in a research note on Friday. They now have a GBX 3,800 ($63.84) price target on the stock. Finally, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Wednesday, April 23rd. They now have a GBX 3,830 ($64.35) price target on the stock. Seven analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and seven have issued a buy rating to the company. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 3,879.24 ($65.18).

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.